REFINE CLINICAL WHOLESALE LIMITED

Company Registration Number:
12263122 (England and Wales)

Unaudited abridged accounts for the year ended 31 October 2025

Period of accounts

Start date: 01 November 2024

End date: 31 October 2025

REFINE CLINICAL WHOLESALE LIMITED

Contents of the Financial Statements

for the Period Ended 31 October 2025

Balance sheet
Notes

REFINE CLINICAL WHOLESALE LIMITED

Balance sheet

As at 31 October 2025


Notes
2025
2024


£
£
Fixed assets
Tangible assets: 3 44,924 5,760
Total fixed assets: 44,924 5,760
Current assets
Stocks: 1,330,278 68,898
Debtors:   2,403,579 1,592,622
Cash at bank and in hand: 29,139 49,911
Total current assets: 3,762,996 1,711,431
Creditors: amounts falling due within one year:   (3,143,009) (1,221,939)
Net current assets (liabilities): 619,987 489,492
Total assets less current liabilities: 664,911 495,252
Creditors: amounts falling due after more than one year:   (19,086) (19,086)
Total net assets (liabilities): 645,825 476,166
Capital and reserves
Called up share capital: 2 2
Profit and loss account: 645,823 476,164
Shareholders funds: 645,825 476,166

The notes form part of these financial statements

REFINE CLINICAL WHOLESALE LIMITED

Balance sheet statements

For the year ending 31 October 2025 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 15 July 2026
and signed on behalf of the board by:

Name: B Tyson
Status: Director

The notes form part of these financial statements

REFINE CLINICAL WHOLESALE LIMITED

Notes to the Financial Statements

for the Period Ended 31 October 2025

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

REFINE CLINICAL WHOLESALE LIMITED

Notes to the Financial Statements

for the Period Ended 31 October 2025

2. Employees

2025 2024
Average number of employees during the period 12 9

REFINE CLINICAL WHOLESALE LIMITED

Notes to the Financial Statements

for the Period Ended 31 October 2025

3. Tangible Assets

Total
Cost £
At 01 November 2024 8,690
Additions 41,620
At 31 October 2025 50,310
Depreciation
At 01 November 2024 2,930
Charge for year 2,456
At 31 October 2025 5,386
Net book value
At 31 October 2025 44,924
At 31 October 2024 5,760